AA
ALLO icon

ALPS Advisors’s Allogene Therapeutics ALLO Stock Holding History

ALPS Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729K Buy
+350,303
New +$769K ﹤0.01% 800
2024
Q4 		– Sell
-175,285
Closed -$491K – 993
2024
Q3 		$491K Buy
175,285
+12,427
+8% +$33.1K ﹤0.01% 615
2024
Q2 		$379K Buy
162,858
+44,172
+37% +$130K ﹤0.01% 665
2024
Q1 		$531K Buy
118,686
+32
+0% +$134 ﹤0.01% 586
2023
Q4 		$381K Sell
118,654
-5,064
-4% -$14.4K ﹤0.01% 708
2023
Q3 		$392K Buy
123,718
+16,515
+15% +$72.4K ﹤0.01% 628
2023
Q2 		$533K Buy
+107,203
New +$580K ﹤0.01% 603
2022
Q4 		– Sell
-78,536
Closed -$848K – 1024
2022
Q3 		$848K Sell
78,536
-6,654
-8% -$90.4K 0.01% 499
2022
Q2 		$971K Buy
+85,190
New +$756K 0.01% 482

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ALPS Advisors's ALLO Position: Q2 2026 in Review

ALPS Advisors opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 350,303 shares worth $729K. The stake represents ﹤0.01% of the portfolio and ranks #800 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in ALLO as recently as Q3 2024.

ALPS Advisors first reported a position in ALLO in Q2 2022 and has held it in 9 quarters since. The position peaked at $971K in Q2 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • ALPS Advisors held 350,303 shares of Allogene Therapeutics worth $729K as of Q2 2026.
  • Allogene Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #800 holding.
  • ALPS Advisors first reported a position in Allogene Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • ALPS Advisors's Allogene Therapeutics position peaked at $971K in Q2 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.